Manipulation of the tumour-associated vasculature to improve tumour therapy

被引:5
作者
ten Hagen, TLM [1 ]
Eggermont, AMM [1 ]
机构
[1] Erasmus Univ, Lab Expt Surg Oncol, Dept Surg Oncol, NL-3000 DR Rotterdam, Netherlands
关键词
tumour vasculature; tumour necrosis factor alpha; solid tumour; stealth liposome; vascular manipulation;
D O I
10.1081/LPR-120004788
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Inhibition of tumour vascular growth, destruction of the tumour associated vasculature (TAV), and manipulation of the endothelial lining of the TAV provide powerful tools for anti-tumour therapy. We previously demonstrated that addition of TNF to chemotherapy improved tumour response. The major effect of TNF is an increased permeability of the tumour vascular bed resulting in augmented accumulation of co-administered drug in the tumour. As the TAV is recognised as a major candidate in tumour therapy it is becoming important to understand antivascular effects better. In our laboratory we examine the effect of immunotherapy on the TAV, and the effect of anti tumour-vascular therapy on tumours. This is studied in animal models, which exhibit similarities with the clinical setting, such as tumour perfusion treatment.
引用
收藏
页码:149 / 154
页数:6
相关论文
共 15 条
[1]   Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion [J].
de Wilt, JHW ;
ten Hagen, TLM ;
de Boeck, G ;
van Tiel, ST ;
de Bruijn, EA ;
Eggermont, AMM .
BRITISH JOURNAL OF CANCER, 2000, 82 (05) :1000-1003
[2]   Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats [J].
de Wilt, JHW ;
Manusama, ER ;
van Tiel, ST ;
van Ijken, MGA ;
ten Hagen, TLM ;
Eggermont, AMM .
BRITISH JOURNAL OF CANCER, 1999, 80 (1-2) :161-166
[3]   Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. [J].
Eggermont A.M. ;
ten Hagen T.L. .
Current Oncology Reports, 2001, 3 (4) :359-367
[4]   Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas - The cumulative multicenter European experience [J].
Eggermont, AMM ;
Koops, HS ;
Klausner, JM ;
Kroon, BBR ;
Schlag, PM ;
Lienard, D ;
vanGeel, AN ;
Hoekstra, HJ ;
Meller, I ;
Nieweg, OE ;
Kettelhack, C ;
BenAri, G ;
Pector, JC ;
Lejeune, FJ .
ANNALS OF SURGERY, 1996, 224 (06) :756-765
[5]  
Gridley DS, 2000, ANTICANCER RES, V20, P4195
[6]   Liposome-encapsulated tumor necrosis factor-α enhances the effects of radiation against human colon tumor xenografts [J].
Kim, DW ;
Andres, ML ;
Li, J ;
Kajioka, EH ;
Miller, GM ;
Seynhaeve, ALB ;
Ten Hagen, TLM ;
Gridley, DS .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (11) :885-897
[7]   Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts [J].
Kristensen, CA ;
Nozue, M ;
Boucher, Y ;
Jain, RK .
BRITISH JOURNAL OF CANCER, 1996, 74 (04) :533-536
[8]   HIGH-DOSE RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA IN COMBINATION WITH INTERFERON-GAMMA AND MELPHALAN IN ISOLATION PERFUSION OF THE LIMBS FOR MELANOMA AND SARCOMA [J].
LIENARD, D ;
EWALENKO, P ;
DELMOTTE, JJ ;
RENARD, N ;
LEJEUNE, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) :52-60
[9]   Endostatin: An endogenous inhibitor of angiogenesis and tumor growth [J].
OReilly, MS ;
Boehm, T ;
Shing, Y ;
Fukai, N ;
Vasios, G ;
Lane, WS ;
Flynn, E ;
Birkhead, JR ;
Olsen, BR ;
Folkman, J .
CELL, 1997, 88 (02) :277-285
[10]  
Ten Hagen TLM, 2000, INT J CANCER, V87, P829, DOI 10.1002/1097-0215(20000915)87:6<829::AID-IJC12>3.0.CO